Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Non-Current Deffered Revenue (2016 - 2023)

Plus Therapeutics (PSTV) has disclosed Non-Current Deffered Revenue for 12 consecutive years, with $1.9 million as the latest value for Q4 2023.

  • On a quarterly basis, Non-Current Deffered Revenue rose 17.1% to $1.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $1.9 million, a 17.1% increase, with the full-year FY2023 number at $1.9 million, up 17.1% from a year prior.
  • Non-Current Deffered Revenue was $1.9 million for Q4 2023 at Plus Therapeutics, up from $1.6 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.9 million in Q4 2023 to a low of $142000.0 in Q1 2019.
  • A 3-year average of $1.2 million and a median of $1.6 million in 2022 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: surged 35.24% in 2019, then grew 17.1% in 2023.
  • Plus Therapeutics' Non-Current Deffered Revenue stood at $142000.0 in 2019, then skyrocketed by 1057.04% to $1.6 million in 2022, then increased by 17.1% to $1.9 million in 2023.
  • Per Business Quant, the three most recent readings for PSTV's Non-Current Deffered Revenue are $1.9 million (Q4 2023), $1.6 million (Q4 2022), and $142000.0 (Q1 2019).